Clinical trial NCT01967251: Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction
Official title: A Randomized, Triple Blind, Placebo-controlled, Parallel-group Trial to Assess the Efficacy, Safety and Dose Response of Udenafil for 12 Weeks in Mexican Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Erectile Dysfunction
Benign Prostatic Hyperplasia
Keywords: Prostatic Hyperplasia
Phosphodiesterase 5 inhibitors
Erectile DysfunctionDrug Therapy
Lead sponsor: Takeda
Sponsor class: INDUSTRY
First posted: 2013-10-22
Enrollment: 0
Sex: MALE
Minimum age (years): 45
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the efficacy, dose-response and safety of udenafil 25 mg, 50 mg and 75 mg every day (q.d.) for 12 weeks in the treatment of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH and for the treatment of erectile dysfunction (ED).

Detailed description: The drug being tested in this study is called Udenafil. Udenafil is being tested to treat lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) and for the treatment of erectile dysfunction (ED). This study will look at the change in lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) and in erectile dysfunction (ED) in people who take Udenafil.

The study will enroll approximately 950 patients. Participants taking BPH or ED medication will enter a 4-week wash out period. Patients not previously treated and those who accomplished the wash out period will enter a placebo (dummy inactive pill) lead-in period of another 4 weeks. Participants will then be randomly assigned (by chance, like flipping a coin) to one of the four treatment groups-which will remain undisclosed to the patient and study doctor during the study (unless there is an urgent medical need):

* Udenafil 25 mg
* Udenafil 50 mg
* Udenafil 75 mg
* Placebo (dummy inactive pill) - this is a tablet that looks like the study drug but has no active ingredient

All participants will be asked to take one tablet at the same time each day throughout the study, and will be asked to keep a Sexual Encounter Profile (SEP) diary.

This multi-centre trial will be conducted in Mexico. The overall time to participate in this study is up to 20 weeks. Participants will make 6 visits to the clinic.

Eligibility criteria: Inclusion Criteria:

1. Men ≥ 45 years of age.
2. Sexually active, with a stable female partner with whom the participant expects to have a relationship for the entire duration of the study.
3. The participant has benign prostatic hyperplasia with lower urinary tract symptoms (BPH-LUTS) according to clinical diagnostic criteria, with ≥ 6 months of evolution at the screening visit.
4. Clinical history of erectile dysfunction (ED) (defined as the inability to achieve or maintain the penile erection to achieve a satisfactory sexual relationship) of at least 3 months of evolution.
5. Freely given informed consent at the screening visit (an essential requirement to participate in the study).
6. Bladder obstruction defined by maximal flow rate (Qmax) of 4-15 mI/sec (with a premicturition volume of 150 to 550 mL evaluated by ultrasound, with a minimum micturition volume of 125 mL) at Visit I immediately prior to active treatment initiation.
7. Total score of ≥ 13 points in the InternationaI Prostate Symptom Score (IPSS) questionnaire at Visit 1, immediately prior to active treatment initiation.

Exclusion Criteria:

1. Participants that are currently taking nitrates, antiandrogens, estrogens, luteninizing hormone-releasing hormone agonist/antagonist, or anabolic steroids at study entry. Participants that are taking a stable dose level of testosterone are not excluded.
2. Post-void residual (PVR) volume ≥ 300 mL, as assessed by ultrasound at the Visit 1.
3. Prostate-specific antigen (PSA) ≥ 10.0 ng/mL at the Visit 1.
4. PSA of 4.0 - 10.0 ng/ml if free PSA is \< 0,25 (25%) at Visit 1.
5. Clinical evidence of prostate cancer.
6. Glycosylated hemoglobin (Hb1Ac) \> 10 % at study entry.
7. Patients who have undergone bladder catheterization due to acute urine retention.
8. Medical history or clinical evidence of any pelvic, bladder or urinary tract condition, or urinary retention that, as judged by the urologist, might compromise protocol compliance.
9. Any surgical procedure in the lower urinary tract (including prostate biopsy) within 30 days prior to the Screening Visit.

Primary outcomes:
measure: Change from Baseline in Total International Prostate Symptom Score (IPSS)
timeFrame: Baseline to Week 12
measure: Change from Baseline in Erectile Function Domain of the International Index of Erectile Function (IIEF)
timeFrame: Baseline and Week 12
Secondary outcomes:
measure: Participants with Adverse Events
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Mexico
country: Mexico
state: Distrito Federal
city: Mexico
country: Mexico
state: Estado de México
city: Guadalajara
country: Mexico
state: Jalisco
city: Morelia
country: Mexico
state: Michoacán
city: Cuernavaca
country: Mexico
state: Morelos
city: Monterrey
country: Mexico
state: Nuevo León
city: Cholula
country: Mexico
state: Puebla
city: Chihuahua
country: Mexico
Study officials:
affiliation: Takeda
name: Medical Director
role: STUDY_DIRECTOR
References: